In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer

Autores
Marín, Gustavo Horacio; Murail, Samuel; Andrini, Laura Beatriz; García, Marcela Nilda; Loisel, Severine; Tuffery, Pierre; Rebollo, Angelita
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere witha given protein–protein interaction (IP) is a promising strategy with potential clinical application.Little is known about the impact of fusing a TPP with an IP, both in terms of internalization andfunctional effect. Here, we analyze these aspects in the context of breast cancer, targeting PP2A/SET interaction, using both in silico and in vivo approaches. Our results support the fact that state-of-theart deep learning approaches developed for protein–peptide interaction modeling can reliably identify good candidate poses for the IP-TPP in interaction with the Neuropilin-1 receptor. The association of the IP with the TPP does not seem to affect the ability of the TPP to bind to Neuropilin-1. Molecular simulation results suggest that peptide IP-GG-LinTT1 in a cleaved form interacts with Neuropilin-1 in a more stable manner and has a more helical secondary structure than the cleaved IP-GG-iRGD.Surprisingly, in silico investigations also suggest that the non-cleaved TPPs can bind the Neuropilin-1 in a stable manner. The in vivo results using xenografts models show that both bifunctional peptides resulting from the combination of the IP and either LinTT1 or iRGD are effective against tumoral growth. The peptide iRGD-IP shows the highest stability to serum proteases degradation while having the same antitumoral effect as Lin TT1-IP, which is more sensitive to proteases degradation.Our results support the development of the TPP-IP strategy as therapeutic peptides against cancer
Facultad de Ciencias Médicas
Materia
Ciencias Médicas
peptide
cancer
breast
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/159988

id SEDICI_819e6e569a5a3c5c116a804569f5d0a9
oai_identifier_str oai:sedici.unlp.edu.ar:10915/159988
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast CancerMarín, Gustavo HoracioMurail, SamuelAndrini, Laura BeatrizGarcía, Marcela NildaLoisel, SeverineTuffery, PierreRebollo, AngelitaCiencias MédicaspeptidecancerbreastThe combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere witha given protein–protein interaction (IP) is a promising strategy with potential clinical application.Little is known about the impact of fusing a TPP with an IP, both in terms of internalization andfunctional effect. Here, we analyze these aspects in the context of breast cancer, targeting PP2A/SET interaction, using both in silico and in vivo approaches. Our results support the fact that state-of-theart deep learning approaches developed for protein–peptide interaction modeling can reliably identify good candidate poses for the IP-TPP in interaction with the Neuropilin-1 receptor. The association of the IP with the TPP does not seem to affect the ability of the TPP to bind to Neuropilin-1. Molecular simulation results suggest that peptide IP-GG-LinTT1 in a cleaved form interacts with Neuropilin-1 in a more stable manner and has a more helical secondary structure than the cleaved IP-GG-iRGD.Surprisingly, in silico investigations also suggest that the non-cleaved TPPs can bind the Neuropilin-1 in a stable manner. The in vivo results using xenografts models show that both bifunctional peptides resulting from the combination of the IP and either LinTT1 or iRGD are effective against tumoral growth. The peptide iRGD-IP shows the highest stability to serum proteases degradation while having the same antitumoral effect as Lin TT1-IP, which is more sensitive to proteases degradation.Our results support the development of the TPP-IP strategy as therapeutic peptides against cancerFacultad de Ciencias Médicas2023-04-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/159988enginfo:eu-repo/semantics/altIdentifier/issn/1999-4923info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-03T11:13:44Zoai:sedici.unlp.edu.ar:10915/159988Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-03 11:13:44.738SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
title In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
spellingShingle In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
Marín, Gustavo Horacio
Ciencias Médicas
peptide
cancer
breast
title_short In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
title_full In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
title_fullStr In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
title_full_unstemmed In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
title_sort In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer
dc.creator.none.fl_str_mv Marín, Gustavo Horacio
Murail, Samuel
Andrini, Laura Beatriz
García, Marcela Nilda
Loisel, Severine
Tuffery, Pierre
Rebollo, Angelita
author Marín, Gustavo Horacio
author_facet Marín, Gustavo Horacio
Murail, Samuel
Andrini, Laura Beatriz
García, Marcela Nilda
Loisel, Severine
Tuffery, Pierre
Rebollo, Angelita
author_role author
author2 Murail, Samuel
Andrini, Laura Beatriz
García, Marcela Nilda
Loisel, Severine
Tuffery, Pierre
Rebollo, Angelita
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
peptide
cancer
breast
topic Ciencias Médicas
peptide
cancer
breast
dc.description.none.fl_txt_mv The combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere witha given protein–protein interaction (IP) is a promising strategy with potential clinical application.Little is known about the impact of fusing a TPP with an IP, both in terms of internalization andfunctional effect. Here, we analyze these aspects in the context of breast cancer, targeting PP2A/SET interaction, using both in silico and in vivo approaches. Our results support the fact that state-of-theart deep learning approaches developed for protein–peptide interaction modeling can reliably identify good candidate poses for the IP-TPP in interaction with the Neuropilin-1 receptor. The association of the IP with the TPP does not seem to affect the ability of the TPP to bind to Neuropilin-1. Molecular simulation results suggest that peptide IP-GG-LinTT1 in a cleaved form interacts with Neuropilin-1 in a more stable manner and has a more helical secondary structure than the cleaved IP-GG-iRGD.Surprisingly, in silico investigations also suggest that the non-cleaved TPPs can bind the Neuropilin-1 in a stable manner. The in vivo results using xenografts models show that both bifunctional peptides resulting from the combination of the IP and either LinTT1 or iRGD are effective against tumoral growth. The peptide iRGD-IP shows the highest stability to serum proteases degradation while having the same antitumoral effect as Lin TT1-IP, which is more sensitive to proteases degradation.Our results support the development of the TPP-IP strategy as therapeutic peptides against cancer
Facultad de Ciencias Médicas
description The combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere witha given protein–protein interaction (IP) is a promising strategy with potential clinical application.Little is known about the impact of fusing a TPP with an IP, both in terms of internalization andfunctional effect. Here, we analyze these aspects in the context of breast cancer, targeting PP2A/SET interaction, using both in silico and in vivo approaches. Our results support the fact that state-of-theart deep learning approaches developed for protein–peptide interaction modeling can reliably identify good candidate poses for the IP-TPP in interaction with the Neuropilin-1 receptor. The association of the IP with the TPP does not seem to affect the ability of the TPP to bind to Neuropilin-1. Molecular simulation results suggest that peptide IP-GG-LinTT1 in a cleaved form interacts with Neuropilin-1 in a more stable manner and has a more helical secondary structure than the cleaved IP-GG-iRGD.Surprisingly, in silico investigations also suggest that the non-cleaved TPPs can bind the Neuropilin-1 in a stable manner. The in vivo results using xenografts models show that both bifunctional peptides resulting from the combination of the IP and either LinTT1 or iRGD are effective against tumoral growth. The peptide iRGD-IP shows the highest stability to serum proteases degradation while having the same antitumoral effect as Lin TT1-IP, which is more sensitive to proteases degradation.Our results support the development of the TPP-IP strategy as therapeutic peptides against cancer
publishDate 2023
dc.date.none.fl_str_mv 2023-04-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/159988
url http://sedici.unlp.edu.ar/handle/10915/159988
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1999-4923
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1842260642750267392
score 13.13397